Comparative interactions of factor IX and factor IXa with human platelets.
Both factor IX and factor IXa were bound to gel filtered platelets in the presence of CaCl2 (2-20 mM) and human alpha-thrombin (0.06-0.2 units/ml) with maximal binding occurring in 10-20 min at 37 degrees C, and rapid reversibility was observed when unlabeled ligands were added in 100-fold molar excess. Competition studies with various coagulation proteins revealed that neither factor XI nor high molecular weight kininogen, at 300-fold molar excess, could compete with 125I-labeled factor IXa for binding sites on thrombin-activated platelets, whereas prothrombin and factor X, in 450-fold molar excess, could displace approximately 15 and 35%, respectively, of bound factor IXa in the absence of added factor VIII. Analysis of saturation binding data in the presence of CaCl2 and thrombin without factors VIII and X indicated the presence of 306 (+/- 57) binding sites per platelet for factor IX (Kd(app) = 2.68 +/- 0.25 nM) and 515 (+/- 39) sites per platelet for factor IXa (Kd = 2.57 +/- 0.14 nM). In the presence of thrombin-activated factor VIII (1-5 units/ml) and factor X (0.15-1.5 microM), the number of sites for factor IX was 316 (+/- 50) with Kd = 2.44 (+/- 0.30) nM and for factor IXa 551 (+/- 48) sites per platelet (Kd = 0.56 +/- 0.05 nM). Studies of competition for bound factor IXa by excess unlabeled factor IX or factor IXa, and direct 125I-labeled factor IXa binding studies in the presence of large molar excesses of factor IX, confirmed the conclusion from these studies that factor IX and factor IXa share approximately 300 low-affinity binding sites per thrombin-activated platelet in the presence of Ca2+ and in the absence of factor VIII and factor X, with an additional 200-250 sites for factor IXa with Kd(app) similar to that for factor IX. The presence of factor VIII and factor X increases by 5-fold the affinity of receptors on thrombin-activated platelets for factor IXa that participate in factor X activation.
Ahmad
S S
SS
Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
Rawala-Sheikh
R
R
Walsh
P N
PN
D001667:Binding, Competitive; D001779:Blood Coagulation Factors; D001792:Blood Platelets / Q000378:metabolism*; D002122:Calcium Chloride / Q000494:pharmacology; D002850:Chromatography, Gel; D004591:Electrophoresis, Polyacrylamide Gel; D005164:Factor IX / Q000378:metabolism*; D015949:Factor IXa; D005169:Factor VIII / Q000494:pharmacology; D015944:Factor VIIIa; D005170:Factor X / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008970:Molecular Weight; D011516:Prothrombin / Q000378:metabolism; D012697:Serine Endopeptidases / Q000378:metabolism*; D013917:Thrombin / Q000494:pharmacology
D001779:Blood Coagulation Factors; D015944:Factor VIIIa; D011516:Prothrombin; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X; D012697:Serine Endopeptidases; D015949:Factor IXa; D013917:Thrombin; D002122:Calcium Chloride